DNA methylation changes in prostate cancer: Current developments and future clinical implementation

Expert Review of Molecular Diagnostics

Volumn 9, Issue 3, 2009, Pages 243-257

  Hoque, Mohammad Obaidul ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA methylation; Prostate cancer; Screening serum; Therapy monitoring; Urine

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALLELE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; DNA METHYLATION; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; URINALYSIS;

BODY FLUIDS; DNA; DNA METHYLATION; FORECASTING; HUMANS; MALE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 66749182280     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.10     Document Type: Review

References (136)

1. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur. J. Cancer 41(6), 858-887 (2005).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
3. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J. Natl Cancer Inst. 94(13), 958-960 (2002).
4. Alers JC, Krijtenburg PJ, Vis AN et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am. J. Pathol. 158(2), 399-406 (2001).
5. Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 169(2), 517-523 (2003).
6. Barratt AL, Coates AS. Screening decreases prostate cancer death: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial. Med. J. Aust. 181 (4), 213-214 (2004).
7. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial. Prostate 38(2), 83-91 (1999).
8. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196 (1998).
9. Bird A. The essentials of DNA methylation. Cell 70(1), 5-8 (1992).
10. Merlo A, Herman JG, Mao L et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1(7), 686-692 (1995).
11. Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95(12), 6870-6875 (1998).
12. Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 23(27), 6569-6575 (2005).
13. Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br. J. Cancer 100(2), 240-245 (2009).
14. Nelson WG, Yegnasubramanian S, Agoston AT et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci. 12, 4254-4266 (2007).
15. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 177(3), 822-831 (2007).
16. Li LC. Epigenetics of prostate cancer. Front. Biosci. 12, 3377-3397 (2007).
17. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
18. Hoque MO, Kim MS, Ostrow KL et al. Genome-wide promoter analysis unc overs portions of the cancer methylome. Cancer Res. 68(8), 2661-2670 (2008).
19. Ngan RK, Lau WH, Yip TT et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann. NY Acad. Sci. 945, 73-79 (2001).
20. Lo YM. Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma. Biomed. Pharmacother. 55(7), 362-365 (2001).
21. Sidransky D, Von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252(5006), 706-709 (1991).
22. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat. Rev. Cancer 7(7), 531-543 (2007).
23. Hoque MO, Begum S, Topaloglu O et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 64(15), 5511-5517 (2004).
24. Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res. 10(7), 2284-2288 (2004).
25. Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006).
26. Hoque MO, Feng Q, Toure P et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 24(26), 4262-4269 (2006).
27. Henrique R, Costa VL, Cerveira N et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J. Mol. Med. 84(11), 911-918 (2006).
28. Henrique R, Jeronimo C, Hoque MO et al. Frequent 14-13-3s promoter methylation in benign and malignant prostate lesions. DNA Cell Biol. 24(4), 264-269 (2005).
29. Henrique R, Jeronimo C, Hoque MO et al. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 14(5), 1274-1278 (2005).
30. Henrique R, Jeronimo C, Teixeira MR et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol. Cancer Res. 4(1), 1-8 (2006).
31. Henrique R, Ribeiro FR, Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res. 13(20), 6122-6129 (2007).
32. Jeronimo C, Henrique R, Hoque MO et al. A qu antitative promoter methylation profile of prostate cancer. Clin. CancerRes. 10(24), 8472-8478 (2004).
33. Jeronimo C, Usadel H, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60(6), 1131-1135 (2002).
34. Nakayama M, Bennett CJ, Hicks JL et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163(3), 923-933 (2003).
35. Lombaerts M, van Wezel T, Philippo K et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial- to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 94(5), 661-671 (2006).
36. Li LC, Shiina H, Deguchi M et al. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem. Biophys. Res. Commun. 321(2), 455-461 (2004).
37. Wang Q, Williamson M, Bott S et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 26(45), 6560-6565 (2007).
38. Kwabi-Addo B, Ren C, Ittmann M. DNA methylation and aberrant expression of sprouty1 in human prostate cancer.Epigenetics 4(1) (2009).
39. Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 66(6), 613-624 (2006).
40. Enokida H, Shiina H, Urakami S et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 11(18), 6582-6588 (2005).
41. Suzuki M, Shigematsu H, Shivapurkar N et al. Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett. 242(2), 222-230 (2006).
42. Bachmann N, Haeusler J, Luedeke M et al. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet. Cytogenet. 182(2), 103-110 (2008).
43. Cui J, Rohr LR, Swanson G et al. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46(3), 249-256 (2001).
44. Padar A, Sathyanarayana UG, Suzuki M et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 9(13), 4730-4734 (2003).
45. Rosenbaum E, Hoque MO, Cohen Y et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 11(23), 8321-8325 (2005).
46. Hanson JA, Gillespie JW, Grover A et al. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl Cancer Inst. 98(4), 255-261 (2006).
47. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 55(3), 199-205 (2003).
48. Woodson K, O'Reilly KJ, Ward DE et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 1(4), 183-186 (2006).
49. Cheng Y, Kim JW, Liu W et al. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate 69(3), 327-335 (2009).
50. Yamanaka M, Watanabe M, Yamada Y et al. ltered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer 106(3), 382-387 (2003).
51. Nelson JB, Lee WH, Nguyen SH et al. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 57(1), 35-37 (1997).
52. Jeronimo C, Henrique R, Campos PF et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J. Clin. Pathol. 56(1), 52-55 (2003).
53. Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64(6), 1975-1986 (2004).
54. Moriyama-Gonda N, Shiina H, Terashima M, Satoh K, Igawa M. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-a. BJU Int. 101(4), 485-491 (2008).
55. Sasaki M, Tanaka Y, Perinchery G et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J. Natl Cancer Inst. 94(5), 384-390 (2002).
56. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-a and ER-p in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 60(12), 3175-3182 (2000).
57. Zhu X, Leav I, Leung YK et al. Dynamic regulation of estrogen receptor-p expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164(6), 2003-2012 (2004).
58. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8(2), 514-519 (2002).
59. Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91(24), 11733-11737 (1994).
60. Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93(22), 1747-1752 (2001).
61. Kim JW, Cheng Y, Liu W et al. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int. J. Cancer 124(3), 734-738 (2009).
62. Sathyanarayana UG, Padar A, M et al. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 9(17), 6395-6400 (2003).
63. Bastian PJ, Ellinger J, Wellmann A et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res. 11(11), 4097-4106 (2005).
64. Jeronimo C, Henrique R, Hoque MO et al. Quantitative RAR§2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 10(12 Pt 1), 4010-4014 (2004).
65. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21(44), 6835-6840 (2002).
66. Shah JN, Shao G, Hei TK, Zhao Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer 8, 284 (2008).
67. Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer 124(1), 88-94 (2009).
68. Guo L, Zhong D, Lau S et al. Sox7 Is an independent checkpoint for p-catenin function in prostate and colon epithelial cells. Mol. Cancer Res. 6(9), 1421-1430 (2008).
69. Aitchison AA, Veerakumarasivam A, Vias M et al. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 68(6), 661-674 (2008).
70. Higuchi T, Nakamura M, Shimada K et al. HRK inactivation associated with promoter methylation and LOH in prostate cancer. Prostate 68(1), 105-113 (2008).
71. Yu YP, Yu G, Tseng G et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 67(17), 8043-8050 (2007).
72. Pulukuri SM, Patibandla S, Patel J, Estes N, Rao JS. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26(36), 5229-5237 (2007).
73. Leiblich A, Cross SS, Catto JW et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene 25 (20), 2953-2960 (2006).
74. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin. Cancer Res. 12(5), 1412-1419 (2006).
75. Vanaja DK, Ballman KV, Morlan BW et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res. 12(4), 1128-1136 (2006).
76. Yu G, Tseng GC, Yu YP et al. CSR1 suppresses tumor growth and metastasis of prostate cancer. Am. J. Pathol. 168(2), 597-607 (2006).
77. Kim H, Lapointe J, Kaygusuz G et al. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res. 65(18), 8118-8124 (2005).
78. Ropke A, Buhtz P, Bohm M et al. Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer. Oncogene 24(44), 6667-6675 (2005).
79. Zhang J, Liu L, Pfeifer GP. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor b gene. Oncogene 23(12), 2241-2249 (2004).
80. Tokumaru Y, Sun DI, Nomoto S, Yamashita K, Sidransky D. Re: is TIG1 a new tumor suppressor in prostate cancer? J. Natl Cancer Inst. 95(12), 919-920 (2003).
81. Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 3(12), 755-763 (2002).
82. Belinsky SA, Liechty KC, Gentry FD et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66(6), 3338-3344 (2006).
83. Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60(21), 5941-5945
84. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9(7), 2673-2677 (2003).
85. Yegnasubramanian S, Lin X, Haffner MC, DeMarzo AM, Nelson WG. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res. 34(3), e19 (2006).
86. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996).
87. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58(3), 335-338 (2001).
88. Cairns P, Esteller M, Herman JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7(9), 2727-2730 (2001).
89. Roupret M, Hupertan V, Yates DR et al. Molecular detection of localize prostate cancer using quantitative methylation- specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 13(6), 1720-1725 (2007).
90. Woodson K, O'Reilly KJ, Hanson JC et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol. 179(2), 508-511; discussion: 511-502 (2008).
91. Vener T, Derecho C, Baden J et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin. Chem. 54(5), 874-882 (2008).
92. Sunami E, Shinozaki M, Higano CS et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin. Chem. 55(3), 559-67 (2009).
93. Reibenwein J, Pils D, Horak P et al. Promoter hypermethylation of GSTP1, AR, and 14-13-3s in serum of prostate cancer patients and its clinical relevance. Prostate 67(4), 427-432 (2007).
94. Bastian PJ, Palapattu GS, Yegnasubramanian S et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J. Urol. 179(2), 529-534; discussion: 534-525 (2008).
95. Ellinger J, Haan K, Heukamp LC et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1), 42-49 (2008).
96. Cottrell S, Jung K, Kristiansen G et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J. Urol. 177(5), 1753-1758 (2007).
97. Bastian PJ, Ellinger J, Heukamp LC et al. Prognostic value of CpG island hypermethylation at PTGS2, RAR-p, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur. Urol. 51(3), 665-674; discussion: 674 (2007).
98. Suzuki M, Shigematsu H, Shames DS et al. DNA methylation- associated inactivation of TGFp-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br. J. Cancer 93(9), 1029-1037 (2005).
99. Bastian PJ, Palapattu GS, Lin X et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11(11), 4037-4043 (2005).
100. Liu ZJ, Maekawa M. Polymerase chain reaction-based methods of DNA methylation analysis. Anal. Biochem. 317(2), 259-265 (2003).
101. Licchesi JD, Herman JG. Methylation- specific PCR. Methods Mol. Biol. 507, 305-323 (2009).
102. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60(21), 5954-5958 (2000).
103. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 24(2), 193-198 (2003).
104. van Engeland M, Weijenberg MP, Roemen GM et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 63(12), 3133-3137 (2003).
105. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
106. Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J. Mol. Med. 84(5), 365-377 (2006).
107. Zeschnigk M, Bohringer S, Price EA et al. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res. 32(16), e125 (2004).
108. Lo YM, Wong IH, Zhang J et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 59(16), 3899-3903 (1999).
109. McCullagh P, Nelder JA. Generalized Linear Models (2nd Edition). Chapman and Hall, London, UK (1989).
110. Kuppuswamy MN, Hoffmann JW, Kasper CK et al. Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (Factor IX) and cystic fibrosis genes. Proc. Natl Acad. Sci. USA 88(4), 1143-1147 (1991).
111. Singer-Sam J, LeBon JM, Dai A, Riggs AD. A sensitive, quantitative assay for measurement of allele-specific transcripts differing by a single nucleotide. PCR Methods Appl. 1(3), 160-163 (1992).
112. Szabo PE, Mann JR. Allele-specific expression and total expression levels of imprinted genes during early mouse development: implications for imprinting mechanisms. Genes Dev. 9(24), 3097-3108 (1995).
113. Greenwood AD, Burke DT. Single nucleotide primer extension: quantitative range, variability, and multiplex analysis. Genome Res. 6(4), 336-348 (1996).
114. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25(12), 2529-2531 (1997).
115. Cottrell SE, Distler J, Goodman NS et al. A real-time PCR assay for DNA- methylation using methylation-specific blockers. Nucleic Acids Res. 32(1), e10 2004).
116. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659-1665 (2001).
117. Sozzi G, Conte D, Mariani L et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61(12), 4675-4678 (2001).
118. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem. 242(1), 84-89 (1996).
119. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 281(5375), 363-365(1998).
120. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 10(8), 789-799 (2004).
121. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37(3), 646-650 (1977).
122. Chang HW, Lee SM, Goodman SN et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl Cancer Inst. 94(22), 1697-1703 (2002).
123. Wang BG, Huang HY, Chen YC et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 63(14), 3966-3968 (2003).
124. Bastian PJ, Yegnasubramanian S, Palapattu GS et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur. Urol. 46(6), 698-708 (2004).
125. Nakayama M, Gonzalgo ML, Yegnasubramanian S et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 91(3), 540-552 (2004).
126. Chuang CK, Chu DC, Tzou RD et al. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev. 31(1), 59-63 (2007).
127. Roupret M, Hupertan V, Catto JW et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 122(4), 952-956 (2008).
128. Rogers CG, Gonzalgo ML, Yan G et al. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J. Urol. 176(5), 2280-2284 (2006).
129. Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression. Annu. Rev. Pathol. 1, 243-271 (2006).
130. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP. Methylation-specific sequencing of GSTP1 gene promoter in circulating/ extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. NY Acad. Sci. 1137, 222-225 (2008).
131. Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin. 54(1), 8-29 (2004).
132. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int. J. Radiat. Oncol. Biol. Phys. 57(4), 944-952 (2003).
133. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol. 20(16), 3376-3385 (2002).
134. Kuban DA, Thames HD, Levy LB et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int. J. Radiat. Oncol. Biol. Phys. 57(4), 915-928 (2003).
135. Karakiewicz PI, Shariat SF, Palapattu GS et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J. Urol. 176(4 Pt 1), 1354-1361; discussion: 1361-1352 (2006).
136. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 17(5), 1499-1507 (1999).